Investors had already braced themselves for a bad quarter and a near-total reset of expectations at small med-tech company Accuray (ARAY), and the company actually came through with a slightly better quarter. Even so, investors apparently didn't like the fact that management didn't improve its order or revenue guidance, and/or the announcement of a $100 million convertible debt offering.
I've spoken at some length regarding my frustrations with Accuray, and my continued interest (and ownership) in the stock comes down to this - Accuray has developed some radiation therapy systems that offer solid advantages over the systems sold by Varian (VAR) and Elekta (OTCPK:EKTAY). If the company can effectively manufacture, market, and support these...
Only subscribers can access this article, which is part of the PRO research library covering 3,628 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: